Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**11C-PHNO** is a radiopharmaceutical imaging agent, specifically a positron emission tomography (PET) radiotracer, used to image **dopamine D2 and D3 receptors** in vivo in humans. It is an **agonist ligand** with a higher affinity for the dopamine D3 receptor compared to the D2 receptor, enabling it to map and quantify these receptor subtypes in the brain and other tissues using PET imaging. Because 11C-PHNO acts as an agonist, its in vivo binding is more sensitive to endogenous dopamine fluctuations than antagonist tracers, making it highly useful for detecting changes in synaptic dopamine and for evaluating neurochemical differences in psychiatric and neurodegenerative disorders. **11C-PHNO** has been used predominantly in research settings to study the dopamine system in the context of schizophrenia, Parkinson's disease, addiction, and more recently, to assess pancreatic beta cell mass in diabetes due to the presence of dopamine receptors in pancreatic tissue[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11C-PHNO.